new study
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
biopearl123
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
Re: new study
RC, thanks for posting this. I doubt this study could be conceived without information shared from the as yet undisclosed and unpublished single agent IMPRESS study. Glad to see things moving forward.
Re: new study
RC - tremendous find.
Searching the Children's Oncology Group website - sponsor of this CT - only 4 results found containing Imetelstat dating back to 2012/2013 - "children with refractory or recurrent solid tumors."
Perhaps we see a Geron PR regarding this latest study in the very new future. Thanks for your post here. -Kmall
https://childrensoncologygroup.org/
Searching the Children's Oncology Group website - sponsor of this CT - only 4 results found containing Imetelstat dating back to 2012/2013 - "children with refractory or recurrent solid tumors."
Perhaps we see a Geron PR regarding this latest study in the very new future. Thanks for your post here. -Kmall
https://childrensoncologygroup.org/
Re: new study
Rccola --- Thank you for this post.
The "Brief Summary" shows some very important initial steps in treating AML, MDS and JMML. This is the first clinical trial, that I am aware of, that combines Imetelstat with "chemotherapy drugs". It calls to attention the importance of Imetelstat in combinations and the safety-factor in using this medicine in juveniles.
==============================================
The "Brief Summary" shows some very important initial steps in treating AML, MDS and JMML. This is the first clinical trial, that I am aware of, that combines Imetelstat with "chemotherapy drugs". It calls to attention the importance of Imetelstat in combinations and the safety-factor in using this medicine in juveniles.
==============================================
Brief Summary (published 2/8/24)
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imetelstat in combination with fludarabine and cytarabine may work better in treating patients with refractory or recurrent AML, MDS, and JMML.